Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Jacksonville Center For Clinical Research - Univ Campus
mi
from
Jacksonville, FL
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Jacksonville Center For Clinical Research - Univ Campus
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Florida Cardiovascular Institute
mi
from
Tampa, FL
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Florida Cardiovascular Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Phillip D. Toth, Md
mi
from
Indianapolis, IN
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Phillip D. Toth, Md
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
L-MARC Research Center
mi
from
Louisville, KY
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
L-MARC Research Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Commonwealth Biomedical Research, LLC
mi
from
Madisonville, KY
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Commonwealth Biomedical Research, LLC
mi
from
Madisonville, KY
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Mgh Cardiac Mr Pet Ct Program
mi
from
Boston, MA
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Mgh Cardiac Mr Pet Ct Program
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Troy Internal Medince Pc/Research
mi
from
Troy, MI
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Troy Internal Medince Pc/Research
mi
from
Troy, MI
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Radiant Research, Inc.
mi
from
Edina, MN
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Radiant Research, Inc.
mi
from
Edina, MN
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Mount Sinai School Of Medicine Imaging Science Laboratories
mi
from
New York, NY
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Mount Sinai School Of Medicine Imaging Science Laboratories
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
The Lipid Center
mi
from
Statesville, NC
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
The Lipid Center
mi
from
Statesville, NC
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Metabolic And Atherosclerosis Research Center
mi
from
Cincinnati, OH
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Metabolic And Atherosclerosis Research Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Sterling Research Group
mi
from
Cincinnati, OH
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Sterling Research Group
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Radiant Research, Inc.
mi
from
Dallas, TX
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Radiant Research, Inc.
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Baylor College of Medicine
mi
from
Houston, TX
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated:  11/6/2015
Mcallen Heart Clinic
mi
from
Mc Allen, TX
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
Status: Enrolling
Updated: 11/6/2015
Mcallen Heart Clinic
mi
from
Mc Allen, TX
Click here to add this to my saved trials
REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)
REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)
Status: Enrolling
Updated:  11/6/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)
REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)
Status: Enrolling
Updated: 11/6/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy Study of the Application of Low Level Laser Light to Treat Venous Stasis Ulcers
A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia ML Scanner (MLS) on Venous Stasis Ulcers
Status: Enrolling
Updated:  11/7/2015
Jeffrey Kenkel, MD
mi
from
Dallas, TX
Efficacy Study of the Application of Low Level Laser Light to Treat Venous Stasis Ulcers
A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia ML Scanner (MLS) on Venous Stasis Ulcers
Status: Enrolling
Updated: 11/7/2015
Jeffrey Kenkel, MD
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy Study of the Application of Low Level Laser Light to Treat Venous Stasis Ulcers
A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia ML Scanner (MLS) on Venous Stasis Ulcers
Status: Enrolling
Updated:  11/7/2015
Luc Teot, MD
mi
from
Montpellier,
Efficacy Study of the Application of Low Level Laser Light to Treat Venous Stasis Ulcers
A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia ML Scanner (MLS) on Venous Stasis Ulcers
Status: Enrolling
Updated: 11/7/2015
Luc Teot, MD
mi
from
Montpellier,
Click here to add this to my saved trials
Effect of Valsartan on Carotid Artery Disease
Effect of Valsartan on Endothelial Function, Oxidative Stress, Carotid Atherosclerosis, and Endothelial Progenitor Cells (EFFERVESCENT)
Status: Enrolling
Updated:  11/9/2015
Emory University School of Medicine
mi
from
Atlanta, GA
Effect of Valsartan on Carotid Artery Disease
Effect of Valsartan on Endothelial Function, Oxidative Stress, Carotid Atherosclerosis, and Endothelial Progenitor Cells (EFFERVESCENT)
Status: Enrolling
Updated: 11/9/2015
Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF
Double Blind Randomized Placebo Controlled Trial of Natrecor in Patients Hospitalized for Decompensated Heart Failure in the Presence of a Normal Left Ventricular Ejection Fraction
Status: Enrolling
Updated:  11/9/2015
University of Medicine and Dentistry of New Jersey/ New Jersey Medical School
mi
from
Newark, NJ
Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF
Double Blind Randomized Placebo Controlled Trial of Natrecor in Patients Hospitalized for Decompensated Heart Failure in the Presence of a Normal Left Ventricular Ejection Fraction
Status: Enrolling
Updated: 11/9/2015
University of Medicine and Dentistry of New Jersey/ New Jersey Medical School
mi
from
Newark, NJ
Click here to add this to my saved trials
The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)
A Phase I/II, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Bone Marrow or Mesenchymal) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.
Status: Enrolling
Updated:  11/9/2015
University of Miami Miller School of Medicine
mi
from
Miami, FL
The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)
A Phase I/II, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Bone Marrow or Mesenchymal) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.
Status: Enrolling
Updated: 11/9/2015
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Birmingham, AL
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
San Francisco, CA
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Washington,
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Ypsilanti, MI
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Tupelo, MS
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Tupelo, MS
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
North Kansas, MO
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
North Kansas, MO
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Belleville, NJ
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Belleville, NJ
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Bronx, NY
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
New York, NY
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
New York, NY
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Greensboro, NC
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Tyler, TX
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Richmond, VA
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage
Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  11/9/2015
Rush University Medical Center
mi
from
Chicago, IL
Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage
Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 11/9/2015
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Education and Supportive Partners Improving Self-Care (ENSPIRE)
A Family Partnership Intervention in Heart Failure
Status: Enrolling
Updated:  11/9/2015
Grady Hospital
mi
from
Atlanta, GA
Education and Supportive Partners Improving Self-Care (ENSPIRE)
A Family Partnership Intervention in Heart Failure
Status: Enrolling
Updated: 11/9/2015
Grady Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Education and Supportive Partners Improving Self-Care (ENSPIRE)
A Family Partnership Intervention in Heart Failure
Status: Enrolling
Updated:  11/9/2015
Crawford Long Hospital
mi
from
Atlanta, GA
Education and Supportive Partners Improving Self-Care (ENSPIRE)
A Family Partnership Intervention in Heart Failure
Status: Enrolling
Updated: 11/9/2015
Crawford Long Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Education and Supportive Partners Improving Self-Care (ENSPIRE)
A Family Partnership Intervention in Heart Failure
Status: Enrolling
Updated:  11/9/2015
Emory University Hospital
mi
from
Atlanta, GA
Education and Supportive Partners Improving Self-Care (ENSPIRE)
A Family Partnership Intervention in Heart Failure
Status: Enrolling
Updated: 11/9/2015
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Education and Supportive Partners Improving Self-Care (ENSPIRE)
A Family Partnership Intervention in Heart Failure
Status: Enrolling
Updated:  11/9/2015
Atlanta Veterans Affairs (VA) Medical Center
mi
from
Decatur, GA
Education and Supportive Partners Improving Self-Care (ENSPIRE)
A Family Partnership Intervention in Heart Failure
Status: Enrolling
Updated: 11/9/2015
Atlanta Veterans Affairs (VA) Medical Center
mi
from
Decatur, GA
Click here to add this to my saved trials
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated:  11/9/2015
Barbara Davis Center for Childhood Diabetes
mi
from
Aurora, CO
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated: 11/9/2015
Barbara Davis Center for Childhood Diabetes
mi
from
Aurora, CO
Click here to add this to my saved trials
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated:  11/9/2015
University of Colorado Denver
mi
from
Aurora, CO
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated: 11/9/2015
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated:  11/9/2015
University of Colorado Hospital
mi
from
Aurora, CO
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated: 11/9/2015
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated:  11/9/2015
University Hospital, the University of Colorado Health Sciences Center
mi
from
Denver, CO
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Enrolling
Updated: 11/9/2015
University Hospital, the University of Colorado Health Sciences Center
mi
from
Denver, CO
Click here to add this to my saved trials
Right to Left Cardiac Shunt Detection
A With-in Subject, Controlled Study to Determine the Sensitivity and Specificity of the Cardiox Flow Detection System for the Detection of Right-to-Left Cardiac Shunts Compared to Transesophageal Echocardiography and Transcranial Doppler Ultrasound
Status: Enrolling
Updated:  11/10/2015
Heart & Vascular Center of Arizona
mi
from
Phoenix, AZ
Right to Left Cardiac Shunt Detection
A With-in Subject, Controlled Study to Determine the Sensitivity and Specificity of the Cardiox Flow Detection System for the Detection of Right-to-Left Cardiac Shunts Compared to Transesophageal Echocardiography and Transcranial Doppler Ultrasound
Status: Enrolling
Updated: 11/10/2015
Heart & Vascular Center of Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials